Moderna has announced a set of additional investments to allow it to increase global supply of its COVID-19 vaccine. ‘We believe there will continue to be significant need for our vaccine into 2022 and 2023’, says the company.
The company also expects to increase 2021 supply to between 800 million and 1 billion doses.
Today's announcement, alongside other news from mRNA heavyweights Pfizer/ BioNTech this month, illustrates how companies and governments are starting to plan for mas supplies of COVID-19 vaccines over the longer term.